期刊文献+

MDTcare模式下的癌痛药学监护实践1例

A Case of Cancer Pain Pharmaceutical Care Practice Under MDTcare Mode
下载PDF
导出
摘要 目的探讨临床药师参与癌痛多学科团队照护(MDTcare)的工作模式。方法通过1例癌痛患者镇痛治疗期间出现阿片类药物相关不良反应,临床药师在MDT团队中提出个体化治疗方案调整建议,参与患者用药指导和教育,阐述了临床药师的重要作用。结果MDTcare模式下,临床药师与医师紧密协作,患者疼痛控制满意。结论作为MDT团队的成员,临床药师通过优化治疗方案,提供药学监护,保障了患者用药安全有效。 OBJECTIVE To explore the working mode of clinical pharmacists participating in cancer pain multidisciplinary team care(MDTcare).METHODS Through a case of opioid-related adverse reactions during the analgesic treatment of a patient with cancer pain,the clinical pharmacist put forward individualized treatment plan adjustment suggestions in the MDT team,participated in the patient′s medication guidance and education,and explained the important role of the clinical pharmacist.RESULTS Clinical pharmacists and physicians worked closely together in MDTcare mode.The patient was satisfied with pain control.CONCLUSION As a member of the MDT team,clinical pharmacists provide pharmaceutical care by optimizing the treatment plan to ensure the safe and effective medication of patients.
作者 李金芩 龚汉明 李晓霞 孙飞 LI Jin-qin;GONG Han-ming;LI Xiao-xia;SUN Fei(Yunnan New Kunhua Hospital,Kunming 650301,China;The First People′s Hospital of Yunnan Province,Kunming 650032,China)
出处 《海峡药学》 2022年第9期97-100,共4页 Strait Pharmaceutical Journal
基金 昆明市卫生科研课题项目(No.2019-03-10-005)。
关键词 MDTcare 癌痛 药物不良反应 药学监护 临床药师 MDTcare Cancer pain Adverse drug reactions Pharmaceutical care Clinical pharmacist
  • 相关文献

参考文献5

二级参考文献33

  • 1重症加强治疗病房病人镇痛和镇静治疗指南(2006)[J].中国实用外科杂志,2006,26(12):893-901. 被引量:215
  • 2Quigley c, wiffen P. A systematic review of hydromor- phone in acute and chronic pain. J Pain Symptom Manage, 2003, 25:169 - 178.
  • 3Murray A, Hagen NA. Hydromorphone. J Pain Symptom Manage, 2005, 29:$57 - 66.
  • 4Moore KT, St-Fleur D, Marricco NC, et al. Steady-state pharmacokinetics of extended-release hydromorphone (OROS hydromorphone): a randomized study inhealthy volunteers. J Opioid Manag, 2010, 6:351 - 358.
  • 5Vandenbossche J, Richarz U, Richards HM. Repeat- dose steady-state pharmacokinetic evaluation of once- daily hydromorphone extended-release (OROS(~) hydromorphone ER) in patients with chronic pain. J Pain Res. 2012, 5:523 - 533.
  • 6Felden L, Walter C, Harder S, et al. Comparative clinical effects of hydromorphone and morphine: a meta-analysis. Br J Anaesth, 2011,107:319-328.
  • 7Smith H, Bruckenthal P. Implications of opioid analgesia for medically complicated patients. Drugs Aging, 2010, 27:417 - 433.
  • 8Wright AW, Mather LE, Smith MT. Hydromorphone- 3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide.Life Sci, 2001,69:409 - 420.
  • 9Durnin C, Hind ID, Ghani SP, et al. Pharmacokinetics of oral immediate-release hydromorphone (DilaudidlR) in subjects with moderate hepatic impairment. Proc West PharmacolSoc, 2001, 44:83 - 84.
  • 10Deandrea S, Montanari M, Moja L, et al. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol, 2008, 19:1985 - 1991.

共引文献336

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部